Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9UM13
UPID:
APC10_HUMAN
Alternative names:
Cyclosome subunit 10
Alternative UPACC:
Q9UM13; D3DNZ7; Q2V500; Q9UG51; Q9Y5R0
Background:
Anaphase-promoting complex subunit 10, also known as Cyclosome subunit 10, plays a pivotal role in cell cycle regulation. It is a component of the anaphase promoting complex/cyclosome (APC/C), a crucial E3 ubiquitin ligase that governs mitosis and G1 phase progression. By mediating ubiquitination and subsequent degradation of target proteins, it primarily facilitates 'Lys-11'-linked polyubiquitin chains formation, with lesser activity towards 'Lys-48'- and 'Lys-63'-linked chains.
Therapeutic significance:
Understanding the role of Anaphase-promoting complex subunit 10 could open doors to potential therapeutic strategies.